The COVID-19 Pandemic and New Clinical Trial Activations

Joseph Unger (junger@fredhutch.org)  
Fred Hutchinson Cancer Research Center  https://orcid.org/0000-0002-5191-0317

Hong Xiao  
Fred Hutchinson Cancer Research Center

Research

Keywords: Covid-19, cancer clinical trials, cardiovascular clinical trials, mental health clinical trials, clinicaltrials.gov

DOI: https://doi.org/10.21203/rs.3.rs-146767/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

The Covid-19 pandemic has caused severe disruptions in care for many patients. A key question is whether the landscape of clinical research has also changed.

Methods

In a retrospective cohort study, we examined the association of the COVID-19 outbreak with new clinical trial activations. Trial data for all interventional and observational oncology, cardiovascular, and mental health studies from January, 2015 through September, 2020 were obtained from clinicaltrials.gov. An interrupted time-series analysis with Poisson regression was used.

Results

We examined 62,252 trial activations. During the initial COVID-19 outbreak (February, 2020 through May, 2020), model-estimated monthly trial activations for U.S.-based studies were only 57% of the expected estimate had the pandemic not occurred (relative risk = 0.57, 95% CI, 0.52 to 0.61, p<.001). For non-U.S.-based studies, the impact of the pandemic was less dramatic (relative risk = 0.77, 95% CI, 0.73 to 0.82, p<.001), resulting in an overall 27% reduction in the relative risk of new trial activations for U.S.-based trials compared to non-U.S.-based trials (relative risk ratio = 0.73, 95% CI, 0.67 to 0.81, p<.001). Although a rebound occurred in the initial reopening phase (June, 2020 through September, 2020), the rebound was weaker for U.S.-based studies compared to non-U.S. based studies (relative risk ratio = 0.87, 95% CI, 0.80 to 0.95, p<.001).

Conclusions

These findings are consistent with the disproportionate burden of COVID-19 diagnoses and deaths during the initial phase of the pandemic in the U.S. Reduced activation of cancer clinical trials will likely slow the pace of clinical research and new drug discovery, with long-term negative consequences for cancer patients. An important question is whether the renewed outbreak period of winter 2020/2021 will have a similarly negative impact on the initiation of new clinical research studies for non-COVID-19 diseases.

Background/aims

The COVID-19 pandemic has caused severe interruptions in care for patients with non-COVID-19 diseases.¹ As research into COVID-19 treatments has dramatically increased, a key question is whether the landscape of clinical research for non-COVID-19 diseases has also changed, especially in the U.S., where a disproportionate number of cases and deaths from COVID-19 have occurred.² This is important since advances in new treatments for patients rely on the conduct of clinical trials, which represent a key final step in proving the efficacy of new therapies. Thus interruptions in the conduct of clinical trial research could slow the development of new treatments for common illnesses.

Our aim was to examine the association of the COVID-19 outbreak with new clinical trial activations.

Methods
To address this, in a retrospective cohort study, we examined the association of the COVID-19 outbreak with new clinical trial activations using data from clinicaltrials.gov, a comprehensive catalog of all registered domestic and international clinical trials. All interventional and observational oncology, cardiovascular, and mental-health studies – the most common clinical research categories – were included. Poisson regression was used to examine whether total monthly trial activations (using study activation date) changed over time. The World Health Organization declared a Public Health Emergency of International Concern on January 30, 2020. Using an interrupted time-series approach, the exposures were landmark timepoint indicator variables describing whether trial activations occurred in: 1) the initial pandemic period (February-May, 2020) versus the pre-pandemic period (2015-January, 2020); and 2) the initial U.S.-based reopening period (June-September, 2020) versus before June, 2020. Comparisons between U.S.-based and non-U.S.-based activations were conducted using interaction tests. The pre-pandemic period was established over 5-years to better model monthly variation. We also included indicator variables for calendar month, with January as the reference, to account for seasonal variation (especially the bolus of trial activations typically observed in January) and potential temporal autocorrelation.

We also evaluated the extent to which the estimated number of trials not activated during the initial pandemic period were “replaced” by the excess number of trials activated in the reopening period. COVID-19 trial activations over time were described.

We followed the STROBE reporting guideline for cohort studies. This study was exempt from institutional review board oversight given no patient-level data. Analyses were conducted in R-version-4.0.2 (R-Project for Statistical Computing) using data obtained November 17, 2020. A 2-sided P < .05 indicated statistical significance.

**Results**

Overall, 62,252 trial activations were examined. Non-COVID-19 trial activations (n = 58,888; 21,684 U.S., 37,204 non-U.S.) included oncology (n = 29,336, 49.8%), cardiovascular (n = 16,239, 27.5%), mental-health (n = 11,283, 19.2%), and multiple (n = 2,030, 3.4%) disease studies. More studies were industry-sponsored (16,022, 27.2%) versus government-sponsored (4,869, 8.3%). Among studies with known data, most were treatment trials (31,129/45,430 = 68.5%) evaluating systemic therapies (26,492/54,180 = 48.9%). COVID-19 activations included n = 3,364 studies (3,364/62,252 = 5.4%; 725 U.S.; 2,639 non-U.S.).

In the U.S., there were fewer trial activations for non-COVID-diseases during the initial pandemic period (Fig. 1A), as the number of COVID-19 trials increased dramatically (Fig. 1B). Model-estimated monthly trial activations were only 57% (201.5; relative risk = 0.57, 95% CI, 0.52 to 0.61, p < .001) of the expected (i.e., counterfactual) estimate had the pandemic not occurred (355.6/month; Table). In contrast, for non-U.S.-based trials, the decrease in monthly trial activations during the pandemic period was more modest, with model-estimated monthly trial activations 77% (437.0/month) of the expected estimate had the pandemic not occurred (565.9/month; relative risk = 0.77, 95% CI, 0.73 to 0.82, p < .001). Thus overall, there was a 27% reduction in the relative risk of new trial activations for U.S.-based trials compared to non-U.S.-based trials (relative risk ratio = 0.73, 95% CI, 0.67–0.81, p < .001; Table).

A rebound occurred in the reopening phase. For U.S.-based trials, model-estimated monthly activations (338.5/month) from June, 2020 to September, 2020 were comparable to expected totals had the pandemic not occurred (351.7/month; relative risk = 0.96, 95% CI, 0.90 to 1.03, p = .25). For non-U.S.-based trials, estimated monthly activations (645.0/month) substantially exceeded the expected total (584.8/month; relative risk = 1.10,
Taken together, the rebound in U.S.-based trial activations was relatively weaker (relative risk ratio = 0.87, 95% CI, 0.80 to 0.95, p < .001).

These patterns were generally similar for oncology, cardiovascular, and mental-health trials (Table).

In the post-pandemic period, for U.S.-based studies, the number of excess trials comprised only 8.6% of the number lost during the pandemic period; for non-U.S. based studies, the number of excess trials was 46.7% of the number lost during the pandemic period.

**Discussion**

The COVID-19 outbreak was associated with a substantial decrease in new clinical trial activations, especially for U.S.-based trials. Trial activations rebounded after the initial pandemic period (June, 2020 through September, 2020), though less so for U.S.-based trials. Moreover, through the end of the analysis period, there remains many fewer new trial activations than what would have occurred in the absence of the COVID-19 pandemic, especially for U.S.-based trials.

These findings are consistent with the disproportionate burden of COVID-19 diagnoses and deaths in the U.S. during the initial outbreak of the pandemic. The reasons for delays or cancellations in trial activations during the initial pandemic period were not identifiable from the data, a study limitation. Regardless, this reduction is exacerbated by trial recruitment challenges for active studies. This reduction also compounds the overall detrimental impact associated with the pandemic due to delays in diagnosis and treatment of new, non-COVID-19 diseases in the U.S. as well as other countries hard hit by the pandemic, such as in the United Kingdom.

**Conclusions**

This reduction in new trial activations for non-COVID-19 diseases is likely to slow the pace of clinical research and new drug discovery, with long-term negative consequences for patients. An important question for researchers and policy-makers is whether the renewed outbreak period of winter 2020/2021 will have a similarly negative impact on the initiation of new clinical research studies for non-COVID-19 diseases.

**Declarations**

Author Contributions: This project was based on an idea of JMU and HX. The analysis was overseen by JMU, conceived by JMU and HX, and conducted by HX. The manuscript was drafted by JMU and was reviewed by both authors. The authors read and approved the final manuscript.

Competing Interests: The authors declare that they have no competing interests.

Funding/Support: Research reported in this publication was supported by the Public Health Sciences Division of the Fred Hutchinson Cancer Research Center.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Availability of data and materials: The data used in this analysis are publicly available through the clinicaltrials.gov web portal.

Ethics approval and consent to participate: This study was exempt from institutional review board oversight given no patient-level data.

Consent for publication: Not applicable, since no patient-level data were used in this study.

References

1. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020;75:2352–71.

2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533–4.

3. Califf RM, Zarin DA, Kramer JM, et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. Jama. 2012;307:1838–47.

4. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.

5. Unger JM, Blanke CD, LeBlanc M, et al. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials. JAMA Netw Open. 2020;3:e2010651.

6. Sharpless NE. COVID-19 and cancer. Science. 2020;368:1290.

7. Maringe C, Spicer J, Morris M, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023–34.

Tables

Table: Comparison of estimated relative change in monthly number of trials in USA and non-USA regions
## Initial Pandemic Period

| Trial Type | Region  | Monthly trial registrations¹ | Relative-Risk (RR)¹ | RR ratio (U.S. versus Non-U.S.)² |
|------------|---------|------------------------------|--------------------|----------------------------------|
|            |         | Fitted value (n) 2015-JAN 2020 | Fitted value (n) FEB-MAY 2020 | Expected value³ FEB-MAY 2020 | RR | 95% CI | p-Value | Risk Ratio | 95% CI | p-Value |
| All Trials | U.S.    | 320.1 (n = 19,524)             | 201.5 (n = 806)      | 355.6              | 0.57 | 0.52, 0.61 | <.001  | 0.73       | 0.67, 0.81 | < .001 |
|            | Non-U.S.| 539.0 (n = 32,876)             | 437.0 (n = 1,748)    | 565.9              | 0.77 | 0.73, 0.82 | < .001 |            |          |        |
| Oncology   | U.S.    | 180.8 (n = 11,028)             | 120.5 (n = 482)      | 196.7              | 0.61 | 0.55, 0.68 | <.001  | 0.76       | 0.67, 0.87 | < .001 |
|            | Non-U.S.| 267.9 (n = 16,344)             | 234.0 (n = 936)      | 290.9              | 0.80 | 0.75, 0.87 | < .001 |            |          |        |
| Cardiovascular | U.S. | 75.6 (n = 4,609)             | 44.0 (n = 176)      | 80.6              | 0.55 | 0.46, 0.65 | < .001  | 0.75       | 0.61, 0.90 | .003   |
|            | Non-U.S.| 189.5 (n = 11,558)             | 135.3 (n = 541)    | 184.6              | 0.73 | 0.66, 0.81 | < .001  |            |          |        |
| Mental health | U.S. | 77.3 (n = 4,713)             | 46.6 (n = 186)      | 93.8              | 0.50 | 0.42, 0.58 | < .001  | 0.69       | 0.56, 0.84 | < .001 |
|            | Non-U.S.| 97.6 (n = 5,955)              | 81.3 (n = 325)      | 112.3              | 0.72 | 0.64, 0.82 | < .001  |            |          |        |

¹ Total counts for each disease exceed the disease-specific counts noted in the text due to the inclusion of multiple disease studies.

² Derived from Poisson regression model, adjusting for calendar month using indicator variables, including interaction terms to derive the risk ratios.

³ Expected (or counterfactual) monthly average number of trial registrations in the absence of the COVID-19 pandemic. Model expected results based on Poisson regression, adjusting for calendar month using indicator variables.
**Initial Pandemic Period**

| Disease          | U.S. | Non-U.S. | Oncology | Non-U.S. | Cardiovascular | U.S. | Non-U.S. | Mental health | Non-U.S. |
|------------------|------|----------|----------|----------|----------------|------|----------|--------------|----------|
| **Fitted value (n)** | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 | JUN-SEP, 2020 |
| **All Trials**   | 338.5 (n = 1, 354) | 645.0 (n = 2,580) | 201.8 (n = 807) | 345.8 (n = 1, 383) | 73.3 (n = 293) | 202.0 (n = 808) | 78.3 (n = 313) | 119.0 (n = 476) |
| **Expected value** | 351.7 | 584.8 | 189.4 | 301.3 | 80.2 | 193.9 | 94.7 | 112.5 |
| **Expected value** | 0.96 | 1.1 | 1.06 | 1.14 | 0.91 | 1.04 | 0.83 | 1.06 |
| **Expected value** | 0.90, 1.03 | 1.05, 1.16 | 0.98, 1.16 | 1.07, 1.23 | 0.80, 1.05 | 0.96, 1.13 | 0.72, 0.94 | 0.95, 1.18 |
| **Expected value** | 0.25 | < .001 | .15 | < .001 | .20 | .35 | .005 | .32 |
| **Expected value** | 0.87 | 0.80, 0.95 | 0.93 | 0.83, 1.03 | 0.88 | 0.75, 1.03 | 0.78 | 0.66, 0.78 |
| **Expected value** | < .001 | 0.18 | 0.11 | 0.32 | 0.005 | 0.005 | 0.005 | 0.005 |

1 Total counts for each disease exceed the disease-specific counts noted in the text due to the inclusion of multiple disease studies.

2 Derived from Poisson regression model, adjusting for calendar month using indicator variables, including interaction terms to derive the risk ratios.

3 Expected (or counterfactual) monthly average number of trial registrations in the absence of the COVID-19 pandemic. Model expected results based on Poisson regression, adjusting for calendar month using indicator variables.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- STROBEchecklistcohort.docx